



**What's New**

**09.12.2016**

**NPPA requests Zydus Cadila Healthcare Ltd., Abbott Healthcare Pvt. Ltd. , Themis, Wockhardt Limited , Unimed Pharma, Aurolab Pharmaceuticals , FDC Limited and IPCA Laboratories Ltd. To furnish details along with all necessary documentary evidence in respect of (i) Dexamethasone 4mg/ml injection (ii) Gentamycin 40mg/ ml injection (iii) Paracetamol Injection 150mg/ml (iv) Hydroxypropyl Methylcellulose injection 2% (v) Tetanus Toxoid injection (vi) Chloroquine Phosphate injection 40mg/ml (vii) Metoclopramide injection 5mg/ml and (viii) Water for injection (ix) Dicyclomine injection 10mg/ml Under Para 11(3).**

NPPA has requested Zydus Cadila Healthcare Ltd., Abbott Healthcare Pvt. Ltd. , Themis, Wockhardt Limited , Unimed Pharma, Aurolab Pharmaceuticals , FDC Limited and IPCA Laboratories Ltd. To furnish details along with all necessary documentary evidence in respect of (i) Dexamethasone 4mg/ml injection (ii) Gentamycin 40mg/ ml injection (iii) Paracetamol Injection 150mg/ml (iv) Hydroxypropyl Methylcellulose injection 2% (v) Tetanus Toxoid injection (vi) Chloroquine Phosphate injection 40mg/ml (vii) Metoclopramide injection 5mg/ml and (viii) Water for injection (ix) Dicyclomine injection 10mg/ml, Under Para 11(3).

NPPA has requested to provide the following information in respect of the subject formulations:

- (I) Whether there is any distortion noticed in the Ceiling prices of the mentioned formulations on account of the pack size, which may perhaps cause some of the packs to be non-remunerative or unviable compared to other pack sizes/single use-multi use.
- (II) Whether there is any special feature on any product which makes this formulation different from others on account of therapeutic benefit, and the rationale for the separate ceiling price.
- (III) Data/ information in respect of overcharging notice(s) issued by NPPA , if any, for the above mentioned formulations.

**Zydus Cadila Healthcare Ltd., Abbott Healthcare Pvt. Ltd. , Themis, Wockhardt Limited , Unimed Pharma, Aurolab Pharmaceuticals , FDC Limited and IPCA Laboratories Ltd.** Have been requested to furnish the above details as soon as possible along with all necessary documentary evidence in support of their contention to enable NPPA to take further necessary action.

["Representation under para 11\(3\)."](#)